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Background: Since proteoglycans (PGs) appear as key partners in chondrosarcoma biology, PG-targeted imaging
using the radiotracer 99mTc-N-(triethylammonium)-3-propyl-[15]ane-N5 (99mTc-NTP 15-5) developed by our group
was previously demonstrated to be a good single-photon emission computed tomography tracer for cartilage
neoplasms. We therefore initiated this new preclinical study to evaluate the relevance of 99mTc-NTP 15-5 imaging
for the in vivo monitoring and quantitative assessment of chondrosarcoma response to zoledronic acid (ZOL) in the
Swarm rat orthotopic model.
Findings: Rats bearing chondrosarcoma in the orthotopic paratibial location were treated by ZOL (100 μg/kg,
subcutaneously) or phosphate-buffered saline, twice a week, from day 4 to day 48 post-tumor implantation.
99mTc-NTP 15-5 imaging was performed at regular intervals with the target-to-background ratio (TBR) determined.
Tumor volume was monitored using a calliper, and histology was performed at the end of the study. From day
11 to day 48, mean TBR values ranged from 1.7 ± 0.6 to 2.3 ± 0.6 in ZOL-treated rats and from 2.1 ± 1.0 to 4.9 ± 0.9
in controls. Tumor growth inhibition was evidenced using a calliper from day 24 and associated to a decrease in PG
content in treated tumor tissues (confirmed by histology).
Conclusions: This work demonstrated two proofs of concept: (1) biphosphonate therapy could be a promising
therapeutic approach for chondrosarcoma; (2) 99mTc-NTP 15-5 is expected to offer a novel imaging modality for the
in vivo evaluation of the extracellular matrix features of chondrosarcoma, which could be useful for the follow-up
and quantitative assessment of proteoglycan ‘downregulation’ associated to the response to therapeutic attempts.
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Introduction
Considering the 10-year survival rate of chondrosarcoma
(from 29% to 83% depending on the subtype and grad-
ing), improving its clinical management is a challenge
and novel therapeutic approaches are needed [1]. This
implies that in vivo markers of the biologic phenotypic* Correspondence: elisabeth.noirault@inserm.fr
1INSERM UMR 990, Université d’Auvergne, BP 184, Rue Montalembert,
Clermont-Ferrand, Cédex 63005, France
Full list of author information is available at the end of the article
© 2013 Miot-Noirault et al.; licensee Springer. T
Commons Attribution License (http://creativeco
reproduction in any medium, provided the origfeatures of chondrosarcoma behavior in the bone envir-
onment could be used as quantitative criteria of grading,
follow-up, and early evaluation of response to therapy.
Since proteoglycans (PGs) appear as key partners in
chondrosarcoma biology, PG-targeted imaging using
the radiotracer 99mTc-N-(triethylammonium)-3-propyl-
[15]ane-N5 (99mTc-NTP 15-5) developed by our group
was expected to be a good single-photon emission com-
puted tomography (SPECT) tracer for the molecular im-
aging of cartilage neoplasms in nuclear medicine [2,3].his is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and


























Days post tumoral implantation
ZOL-treated
Controls
Figure 1 Representative time course of the mean tumor
volume ± standard deviation of ZOL-treated and control






Figure 2 Histological analysis of tumor tissue at the end of the study
were stained with hematoxylin-eosin (A, B, D, E) or with alcian blue (C, F).
ZOL, zoledronic acid.
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chondrosarcoma therapeutic management difficult [4]. The
bisphosphonate zoledronic acid (ZOL) has demonstrated
its therapeutic interest in a variety of tumors affecting
the bones, such as osteosarcoma, Ewing's sarcoma, and
chondrosarcoma [5-7].
This study was therefore initiated in the well-
characterized Swarm rat chondrosarcoma (SRC) orthotopic
model to determine the relevance of 99mTc-NTP 15-5 im-
aging for an early quantitative characterization of chon-
drosarcoma response to ZOL.Methods
Protocols were performed under the authorization of the
French Directorate of Veterinary Services (Authorization
No. C63-113-10) and were conducted under the supervi-
sion of authorized investigators in accordance with the





: control (A to C) and ZOL-treated (D to F) groups. The tumor slices
Magnification: ×50 (C), ×100 (B, D, E, F), and ×200 (A). CT, controls;
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Experiments were conducted on 24 male Sprague Dawley
rats (Charles River, L'Arbresle, France). The SRC model
was a generous gift from Dr. P.A. Guerne (Switzerland) as
tissue fragments, which were frozen until use. Allograft
transplantation of a 10-mm3 SRC fragment was performed
on the right hindlimb in the paratibial location of the
anesthetized animals (isoflurane (Abbott, Rungis, France)
in air (1.5%, 1 L/min)) associated with an intramuscular
injection of 100 mg/kg of ketamine (Imalgene®, Rhone
Merieux, Lyon, France), as published [3,6,8].CT
day 4 day 16 day 36AZOL treatment
ZOL was kindly provided as a research-grade disodium
salt by Novartis Pharma AG (Basel, Switzerland). Rats
were randomly divided into two groups:
1. ZOL-treated: subcutaneous administration of 100
μg/kg twice a week from day 4 to day 48 after
implantation (n = 12)
2. Control: PBS in the same conditions (n = 12)ZOL ***Tumor growth assessment
Tumor volume was calculated from calliper measure-
ment of the largest (L) and smallest (S) perpendicular
tumor diameters, using the formula: V(mm3) = 0.5 × L ×
S2 [3]. Data were expressed as mean ± standard devi-
ation. At each time point, the tumor volumes of ZOL
and controls were compared by analysis of variance
(ANOVA) with a level of significance set at p < 0.05.B
* *
*
Figure 3 99mTc-NTP 15-5 imaging of control and ZOL-treated
groups. (A) Representative in vivo scintigraphic images of the
tumor-bearing hindlimb obtained for controls and ZOL-treated
animals at various stages of the study. (B) Semi-quantitative analysis
of 99mTc-NTP 15-5 imaging: results are expressed as mean TBR
values ± standard deviation. CT, controls; ZOL, zoledronic acid-
treated; TBR, target-to-background ratio. The asterisk indicates
p < 0.05.99mTc-NTP 15-5 imaging
99mTc-NTP 15-5 imaging was performed at days 4
(before treatment), 11, 16, 24, 36, and 48 after implan-
tation. NTP 15-5 was radiolabeled with 99mTc as
described [3].
Acquisitions (10-min duration, 15% window at 140 keV)
of each hindlimb of anesthetized animals positioned over
a 10-cm collimator of a small-animal gamma camera
(γImager, Biospace, Paris, France) were performed, 30 min
after i.v. administration of 30 MBq of radiotracer. Fixed-
size regions of interest (ROIs) were delineated over the
tumor, adjacent muscles, and contralateral muscles, and
average counts (cpm/mm2) were obtained. The use of ac-
tivity profile for ROI placement ensured easy, reproducible
positioning of the ROI for serial images.
At each time point and for each animal, the target-
to-background ratio (TBR) was calculated as follows: TBR =
Average count in the tumor (cpm/mm2) / Average count in
the contralateral muscle (cpm/mm2). Data were expressed
as mean ± standard deviation.Analysis of data with multiple comparisons was per-
formed by repeated-measures ANOVA followed by Tukey’s
post-test, with a level of significance set at p < 0.05.
Histology
At the end of the study, tumors fixed in 4% formalin
were embedded in paraffin, sectioned (5 μm), and
stained with hematoxylin-eosin and alcian blue (AB).
Results
ZOL inhibited tumor growth
As shown in Figure 1, ZOL inhibited tumor growth as
compared to controls: From day 24 to day 48, a signifi-
cant (p < 0.05) difference in tumor volume was observed
between control and treated groups.
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histology (Figure 2): whereas controls showed nuclear
atypia, anisokaryosis, mitosis, lobular arrangement of the
tumor, and metachromasia (Figure 2A,B,C), ZOL-treated
animals demonstrated fibrous and inflammatory remo-
deling patterns of tumor regression (Figure 2D,E). Meta-
chromasia, reflecting PG content, was also decreased in
ZOL-treated animals as compared to controls (Figure 2F
versus Figure 2C).
99mTc-NTP 15-5 monitoring of in vivo chondrosarcoma
response to ZOL
As illustrated in Figure 3A, for representative animals,
99mTc-NTP 15-5 accumulation was observed in the
joints and at the sites of tumor implantation as early as
day 4. As pathology evolved, a weaker radiotracer accu-
mulation was observed in ZOL-treated tumors as com-
pared to controls.
From day 11 to day 48, mean TBR values ranged from
1.7 ± 0.6 to 2.3 ± 0.6 in ZOL-treated rats and from 2.1 ±
1.0 to 4.9 ± 0.9 in controls (Figure 3B). Differences in
TBR between treated rats and controls were statistically
significant (p < 0.05) from day 24 to day 48. Repeated-
measures ANOVA revealed both a significant ‘between-
group effect’ as well as a within-subject effect (group *
time).
Discussion
A few years ago, Heymann's group published the thera-
peutic relevance of using ZOL in the SRC model [6]. Since
then, others have reported the promising effects of
bisphosphonates not only on chondrosarcoma prolifera-
tion and invasion in vitro, but also in clinical practice
[7,9,10]. In clinics, chondrosarcoma therapeutic response
is still evaluated by conventional imaging by measuring
anatomical tumor size reduction [11]. Unlike the late ef-
fects of anticancer therapy on tumor size, molecular and
metabolic changes are well recognized to be induced
much earlier, before morphological changes occur [12].
Our previous study demonstrated 99mTc-NTP 15-5 to
be a promising SPECT tracer for the molecular imaging of
cartilage neoplasms in nuclear medicine [3]. 99mTc-NTP
15-5 appeared of particular interest since radiotracers
currently available in clinics such as 201Tl, 99mTc-MIBI,
99mTc-tetrofosmin, 99mTc-DMSA(V), and 18F-FDG have
evidenced limitations for imaging chondrosarcoma with
low cellularity and high chondrogenic matrix [13].
The results reported in this new study bring additional
data in favor of 99mTc-NTP 15-5 imaging for the in vivo
follow-up of chondrosarcoma and more especially the
semi-quantitative assessment of therapeutic response
in vivo, with TBR values being significantly decreased in
the treated group with respect to controls from day 24.
Chondrosarcoma growth inhibition was confirmed bycalliper measurement from day 24 and characterized at the
tissue level by histology: interestingly, AB staining
evidenced a huge decrease in glycosaminoglycan content in
ZOL as compared to controls. Such PG ‘downregulation’
reflects the tumor proliferation inhibition at the extracellu-
lar matrix level and is expected to be at the origin of the de-
creased accumulation of the 99mTc-NTP 15-5 radiotracer in
tumors responding to ZOL.
Conclusion
99mTc-NTP 15-5 is expected to offer a novel imaging
modality for the semi-quantitative evaluation of PG
in vivo as markers of the extracellular matrix features of
chondrosarcoma, which could be useful for the follow-
up and evaluation of the response to therapeutic at-
tempts. Combining chondrosarcoma functional imaging
at the PG level with relevant targeted therapies may rep-
resent the opportunity to bridge the gap between pre-
clinical and clinical testing, which is of real need for
improving the management of this pathology.
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